nasvax ltd (NSVX:Tel Aviv)
nasvax ltd (NSVX) Snapshot
|
Open
$8.40
|
Previous Close
$8.40
|
|
|
Day High
$8.10
|
Day Low
$7.40
|
|
|
52 Week High
06/10/12 - $65.00
|
52 Week Low
05/23/13 - $7.40
|
|
|
Market Cap
6.9M
|
Average Volume 10 Days
156.8K
|
|
|
EPS TTM
$-0.32
|
Shares Outstanding
90.6M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
nasvax ltd (NSVX) Related Businessweek News
No Related Businessweek News Foundnasvax ltd (NSVX) Details
NasVax Ltd. develops vaccines and immunotherapeutics in Israel. The company’s products include anti-CD3 MAb, a vaccine for the treatment of inflammatory and autoimmune diseases, which is in phase I/2 a clinical trail; and intramuscular and intranasal influenza vaccines, which are in phase I/2 a clinical study. It is also developing pneumococcal vaccine, which is in preclinical stage to protect immunity against pneumococcal strains; and an intramuscular Hepatitis B vaccine that is in preclinical stage. NasVax Ltd. is based in Ness-Ziona, Israel.
nasvax ltd (NSVX) Key Developments
NasVax Ltd., Special/Extraordinary Shareholders Meeting, Feb 10, 2013., at 11:00 Israel Standard Time.
NasVax Ltd. Presents at 5th Annual World Vaccine Congress Asia 2011, Jun-23-2011 12:10 PM. Venue: Grand Hyatt Hotel, Singapore. Speakers: Rom Eliaz, Chief Executive Officer.
Antitope Ltd. has entered into research collaboration with NasVax Ltd. for the generation of monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. Under the collaboration, Antitope will apply its Composite Human Antibody(TM) technology to generate fully-humanized antibodies. The resulting fully-humanized antibodies will be devoid of T cell epitopes and will have a reduced risk of clinical immunogenicity.
| Recently Viewed | |||
| NSVX:IT | 7.60 | -0.80 |  |
| Company | Last | Change | |
| No competitor information is available for NSVX. | |||
| View Industry Companies | |||
Industry Analysis
NSVX
Industry Average
| Valuation | NSVX | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact NASVAX LTD, please visit www.nasvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
